Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences
|
September 25, 2013
Spindle orientation and epidermal morphogenesis
Anita Kulukian, Elaine Fuchs
Developmental Cell
|
January 22, 2009
Unattached kinetochores catalyze production of an anaphase inhibitor that requires a Mad2 template to prime Cdc20 for BubR1 binding
Anita Kulukian, Joo Seok Han, Don W Cleveland
Journal of Cell Science
|
July 25, 2017
Meeting report - New York Symposium on Quantitative Biology of the Cell
Chenshu Liu, Carmen Taveras, Anita Kulukian, et al.
The Journal of Cell Biology
|
November 10, 2010
Cep152 interacts with Plk4 and is required for centriole duplication
Emily M Hatch, Anita Kulukian, Andrew J Holland, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 19, 2015
Epidermal development, growth control, and homeostasis in the face of centrosome amplification
Anita Kulukian, Andrew J Holland, Benjamin Vitre, et al.
Molecular Cell
|
June 25, 2013
Catalytic assembly of the mitotic checkpoint inhibitor BubR1-Cdc20 by a Mad2-induced functional switch in Cdc20
Joo Seok Han, Andrew J Holland, Daniele Fachinetti, et al.
Molecular Cancer Therapeutics
|
April 4, 2020
Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
Anita Kulukian, Patrice Lee, Janelle Taylor, et al.
Nature
|
October 19, 2017
Inflammatory memory sensitizes skin epithelial stem cells to tissue damage
Shruti Naik, Samantha B Larsen, Nicholas C Gomez, et al.
Nature
|
July 6, 2018
Author Correction: Inflammatory memory sensitizes skin epithelial stem cells to tissue damage
Shruti Naik, Samantha B Larsen, Nicholas C Gomez, et al.
Cancer Research Communications
|
September 18, 2023
HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
Devra Olson, Janelle Taylor, Kelsi Willis, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences
|
September 25, 2013
Spindle orientation and epidermal morphogenesis
Anita Kulukian, Elaine Fuchs
Developmental Cell
|
January 22, 2009
Unattached kinetochores catalyze production of an anaphase inhibitor that requires a Mad2 template to prime Cdc20 for BubR1 binding
Anita Kulukian, Joo Seok Han, Don W Cleveland
Journal of Cell Science
|
July 25, 2017
Meeting report - New York Symposium on Quantitative Biology of the Cell
Chenshu Liu, Carmen Taveras, Anita Kulukian, et al.
The Journal of Cell Biology
|
November 10, 2010
Cep152 interacts with Plk4 and is required for centriole duplication
Emily M Hatch, Anita Kulukian, Andrew J Holland, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
November 19, 2015
Epidermal development, growth control, and homeostasis in the face of centrosome amplification
Anita Kulukian, Andrew J Holland, Benjamin Vitre, et al.
Molecular Cell
|
June 25, 2013
Catalytic assembly of the mitotic checkpoint inhibitor BubR1-Cdc20 by a Mad2-induced functional switch in Cdc20
Joo Seok Han, Andrew J Holland, Daniele Fachinetti, et al.
Molecular Cancer Therapeutics
|
April 4, 2020
Preclinical Activity of HER2-Selective Tyrosine Kinase Inhibitor Tucatinib as a Single Agent or in Combination with Trastuzumab or Docetaxel in Solid Tumor Models
Anita Kulukian, Patrice Lee, Janelle Taylor, et al.
Nature
|
October 19, 2017
Inflammatory memory sensitizes skin epithelial stem cells to tissue damage
Shruti Naik, Samantha B Larsen, Nicholas C Gomez, et al.
Nature
|
July 6, 2018
Author Correction: Inflammatory memory sensitizes skin epithelial stem cells to tissue damage
Shruti Naik, Samantha B Larsen, Nicholas C Gomez, et al.
Cancer Research Communications
|
September 18, 2023
HER2-Selective and Reversible Tyrosine Kinase Inhibitor Tucatinib Potentiates the Activity of T-DM1 in Preclinical Models of HER2-positive Breast Cancer
Devra Olson, Janelle Taylor, Kelsi Willis, et al.
Page
of 2